$947.87
0.32%
Nasdaq, Nov 17, 03:59 pm EST. Closed.
ISIN
US04016X1019
Symbol
ARGX

argenx SE ADR Stock price

$950.95
+131.81 16.09% 1M
+174.69 22.50% 6M
+110.00 13.08% YTD
+21.34 2.30% 1Y
+465.72 95.98% 3Y
+649.73 215.70% 5Y
+927.95 4,034.57% 10Y
+927.95 4,034.57% 20Y
Nasdaq, Closing price Mon, Nov 16 2026
-9.09 0.95%
ISIN
US04016X1019
Symbol
ARGX
Industry

AI Insights on argenx SE ADR Insights AI Insights on argenx SE ADR

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Is argenx SE ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,087 stocks worldwide.

Key metrics

Basic
Market capitalization
$60.7b
Enterprise Value
$55.6b
Net debt
-
Cash
-
Shares outstanding
-
Valuation
P/E
32.9
P/S | estimate
10.4 | 9.5
EV/Sales | estimate
9.6 | 8.7
EV/FCF | ex SBC
67.8 | 98.3
P/B
7.2
Financial Health
Equity Ratio
84.3%
Return on Equity
17.6%
ROCE
20.6%
ROIC
43.9%
Debt/Equity
-
Financials
Revenue | estimate
$5.8b | $6.4b
EBITDA
-
EBIT
$1.7b
Net Income
$1.9b
Free Cash Flow | ex SBC
- | -
Growth
Revenue | estimate
61.4% | 53.4%
EBITDA
-
EBIT
117.5%
Net Income
22.4%
Free Cash Flow
-
Margin
Gross
90.0%
EBITDA
-
EBIT
29.9%
Net
32.3%
Free Cash Flow | ex SBC
- | -
More
EPS
$28.9
FCF per Share
-
Short interest
2.3%
Employees
2k
Rev per Employee
$2.2m

argenx SE ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

26 Analysts have issued a argenx SE ADR forecast:

23x Buy
88%
3x Hold
12%

Analyst Opinions

26 Analysts have issued a argenx SE ADR forecast:

Buy
88%
Hold
12%

argenx SE ADR Events

Past Events
OCT
22
Q3 2026 Earnings Call
26 days ago
SEP
14
Morgan Stanley 24th Annual Global Healthcare Conference
2 months ago
AUG
17
Special Call - argenx SE
3 months ago
JUL
27
argenx SE, Forte Biosciences, Inc. - M&A Call
4 months ago
JUL
23
Q2 2026 Earnings Call
4 months ago
JUN
23
Special Call - argenx SE
5 months ago
JUN
9
Goldman Sachs 47th Annual Global Healthcare Conference 2026
5 months ago
MAY
12
Bank of America Global Healthcare Conference 2026
6 months ago
MAY
7
Q1 2026 Earnings Call
6 months ago
FEB
26
Q4 2025 Earnings Call
9 months ago
JAN
12
44th Annual J.P. Morgan Healthcare Conference
10 months ago
OCT
30
Q3 2025 Earnings Call
about one year ago

Financial data from argenx SE ADR

Sep '26
+/-
%
5,819 5,819
61% 61%
100%
- Direct Costs 581 581
55% 55%
10%
5,238 5,238
62% 62%
90%
- Selling and Administrative Expenses 1,793 1,793
47% 47%
31%
- Research and Development Expense 1,791 1,791
39% 39%
31%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 1,741 1,741
117% 117%
30%
Net Profit 1,877 1,877
22% 22%
32%

In millions USD.

Don't miss a Thing! We will send you all news about argenx SE ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

argenx SE ADR Stock News

Neutral
GlobeNewsWire
●
9 days ago
Argenx to acquire UNP for $550 million upfront plus contingent value rights tied to development and regulatory milestones, for total potential value of up to approximately $1.15 billion
Neutral
GlobeNewsWire
●
9 days ago
Amsterdam, the Netherlands, November 9, 2026, 07:00 CET – argenx (Euronext & Nasdaq: ARGX), the immunology innovation company, today announced a definitive agreement to acquire Unnatural Products, Inc. (UNP), adding a macrocyclic peptide discovery engine to its immunology innovation capabilities. argenx, which already holds a minority stake in UNP, will acquire all remaining shares in a transac...
Neutral
GlobeNewsWire
●
10 days ago
ALKIVIA met its primary and key secondary endpoints in the combined IMNM and DM population First Phase 3 study to demonstrate statistically significant and clinically meaningful benefit in IMNM, an autoimmune myositis subtype with no approved therapies Consistent, clinically meaningful treatment effect in DM, demonstrating improvements in muscle strength and skin disease activity November 7, 20...
More argenx SE ADR News

Company Profile

argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands.

Head office Netherlands
CEO Mr. Hauwermeiren
Employees 1,863
Founded 2008
Website www.argenx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today